Alteogen closed with a sharp gain on the 29th, validating positive assessments from the securities industry. On this day, Alteogen finished trading at 373,000 KRW, up 29,500 KRW (8.59%) from the previous trading day. Steady buying pressure continued to flow in during the session, sustaining a strong upward trend.

In early June, Daishin Securities published a new report on Alteogen, maintaining its investment opinion of 'BUY' and a target price of 500,000 KRW. This analysis suggests an additional upside potential of approximately 36.6% based on the previous day's closing price. Notably, this target price is identical to the level presented on May 20, and it is interpreted that investor sentiment has improved significantly, coupled with expectations for the expansion of technology licensing.

Hong Ga-hye, a researcher at Daishin Securities, positively evaluated the mitigated risks associated with key U.S. patents. Researcher Hong cited the increased likelihood of signing new license-out agreements and the anticipated inflow of milestone payments driven by the expanded sales of the Keytruda subcutaneous (SC) injection product as key investment points.

The broader securities industry is focusing on the growing possibility of expanded partnerships with global pharmaceutical companies once patent uncertainties are resolved. It is projected that future technology transfer outcomes and the signing of additional new contracts will serve as key variables determining Alteogen's enterprise value.

[This article was written with the assistance of AI. This article does not constitute investment advice, and any losses resulting from IPO investments may be borne by the investor.]